Allianz Asset Management GmbH Has $5.74 Million Stock Holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Allianz Asset Management GmbH decreased its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 12.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 40,237 shares of the specialty pharmaceutical company’s stock after selling 5,909 shares during the period. Allianz Asset Management GmbH owned 0.07% of Jazz Pharmaceuticals worth $5,737,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. JPMorgan Chase & Co. boosted its holdings in Jazz Pharmaceuticals by 16.7% during the first quarter. JPMorgan Chase & Co. now owns 2,262,159 shares of the specialty pharmaceutical company’s stock worth $323,376,000 after buying an additional 324,080 shares during the last quarter. LSV Asset Management boosted its holdings in Jazz Pharmaceuticals by 31.0% during the first quarter. LSV Asset Management now owns 1,001,650 shares of the specialty pharmaceutical company’s stock worth $143,185,000 after buying an additional 237,190 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in Jazz Pharmaceuticals by 1.2% during the second quarter. Janus Henderson Group PLC now owns 697,152 shares of the specialty pharmaceutical company’s stock worth $99,386,000 after buying an additional 8,473 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in Jazz Pharmaceuticals by 7.6% during the second quarter. Acadian Asset Management LLC now owns 482,681 shares of the specialty pharmaceutical company’s stock worth $68,811,000 after buying an additional 33,929 shares during the last quarter. Finally, Amundi Pioneer Asset Management Inc. boosted its holdings in Jazz Pharmaceuticals by 10.7% during the first quarter. Amundi Pioneer Asset Management Inc. now owns 410,994 shares of the specialty pharmaceutical company’s stock worth $58,750,000 after buying an additional 39,812 shares during the last quarter. Hedge funds and other institutional investors own 87.83% of the company’s stock.

In related news, Director Catherine A. Sohn sold 726 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $135.65, for a total value of $98,481.90. Following the sale, the director now owns 9,574 shares of the company’s stock, valued at approximately $1,298,713.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Paul Treacy sold 4,371 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $137.40, for a total value of $600,575.40. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by company insiders.

A number of brokerages have issued reports on JAZZ. Royal Bank of Canada set a $184.00 target price on Jazz Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, July 3rd. ValuEngine cut Jazz Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday. BidaskClub cut Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, September 7th. Barclays raised their target price on Jazz Pharmaceuticals from $164.00 to $180.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Finally, Mizuho set a $148.00 target price on Jazz Pharmaceuticals and gave the stock a “hold” rating in a report on Wednesday, July 3rd. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and ten have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $169.86.

NASDAQ JAZZ opened at $130.93 on Friday. The firm has a market cap of $7.41 billion, a P/E ratio of 10.70, a P/E/G ratio of 1.05 and a beta of 1.10. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.71 and a quick ratio of 3.52. The stock’s 50-day moving average is $133.13 and its 200-day moving average is $134.80. Jazz Pharmaceuticals PLC has a one year low of $113.52 and a one year high of $169.82.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $3.65 EPS for the quarter, topping the Zacks’ consensus estimate of $3.16 by $0.49. The company had revenue of $534.13 million for the quarter, compared to analyst estimates of $507.23 million. Jazz Pharmaceuticals had a return on equity of 27.72% and a net margin of 32.99%. Jazz Pharmaceuticals’s revenue was up 6.7% compared to the same quarter last year. During the same quarter last year, the firm posted $3.49 earnings per share. Equities analysts anticipate that Jazz Pharmaceuticals PLC will post 13.44 EPS for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Read More: Beige Book

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.